State Street’s Immix Biopharma IMMX Stock Holding History

State Street’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.75M	Buy	191,910 +94,550	+97%	+$694K	﹤0.01%	3337
2025 Q4	$509K	Sell	97,360 -1,600	-2%	-$6.58K	﹤0.01%	3670
2025 Q3	$207K	Buy	98,960 +56,000	+130%	+$134K	﹤0.01%	3905
2025 Q2	$88.9K	Hold	42,960	–	–	﹤0.01%	3998
2025 Q1	$72.2K	Hold	42,960	–	–	﹤0.01%	4032
2024 Q4	$94.5K	Hold	42,960	–	–	﹤0.01%	3998
2024 Q3	$64K	Hold	42,960	–	–	﹤0.01%	4056
2024 Q2	$85.1K	Hold	42,960	–	–	﹤0.01%	4046
2024 Q1	$132K	Hold	42,960	–	–	﹤0.01%	3973
2023 Q4	$297K	Hold	42,960	–	–	﹤0.01%	3784
2023 Q3	$147K	Hold	42,960	–	–	﹤0.01%	4011
2023 Q2	$116K	Hold	42,960	–	–	﹤0.01%	4198
2023 Q1	$78.2K	Hold	42,960	–	–	﹤0.01%	4393
2022 Q4	$98.4K	Hold	42,960	–	–	﹤0.01%	4374
2022 Q3	$58K	Buy	42,960 +4,400	+11%	+$9.62K	﹤0.01%	4624
2022 Q2	$100K	Buy	+38,560	New	+$75.3K	﹤0.01%	4537

Other funds holding IMMX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

State Street's IMMX Position: Q1 2026 in Review

State Street increased its Immix Biopharma (IMMX) stake by 97% in Q1 2026, buying an estimated $694K and bringing the position to 191,910 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3337.

State Street first reported a position in IMMX in Q2 2022 and has held it in 16 quarters since. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

State Street held 191,910 shares of Immix Biopharma worth $1.75M as of Q1 2026.
State Street bought 94,550 Immix Biopharma shares in Q1 2026, an estimated $694K.
Immix Biopharma made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3337 holding.
State Street first reported a position in Immix Biopharma in Q2 2022 and has held it in 16 quarters since.
77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.